Insmed stock has delivered a very large 3 year return, yet current valuation checks and recent share price swings present a more cautious picture around what investors are now paying for that performance.

• Insmed has returned about 4.4x over the past 3 years, which places extra focus on whether the current price still leaves room for attractive long term returns.
• Positive 12 month data for treprostinil palmitil inhalation powder and progression toward a Phase 3 trial can support growth expectations, while the inherent clinical and regulatory risks around that program may weigh on how much investors are willing to pay today.
• With a valuation score of 3 out of 6, Insmed screens as a mixed picture rather than a clear bargain or clear overvaluation on the broader checks.

The issue now is whether Insmed's current share price already reflects the recent progress in its pipeline, or if the mixed valuation signals still leave enough upside to justify the risk.

Has Insmed Run Too Far on Sales?

P/S is often a cleaner yardstick for a company like Insmed that is still reporting losses, because it relates the share price directly to current sales rather than earnings that are affected by heavy research spending.

Insmed trades on a P/S of about 28.7x, which is well above both the biotech industry average of 11.0x and the peer group average of roughly 6.5x. The modelled fair P/S multiple, which blends factors such as the company’s risk profile, margins and size into a tailored benchmark, is about 19.9x. This leaves the current valuation several turns above what this framework suggests as a more balanced level, even after the recent positive 12 month data for treprostinil palmitil inhalation powder and plans for a Phase 3 trial.

On this P/S multiple, Insmed stock currently screens as overvalued on this metric.

The Insmed Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Insmed pick up where the valuation questions above leave off. They spell out which future paths for Insmed's growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. These narratives sit on Simply Wall St's Community page as structured scenarios that each lay out the assumptions behind their fair value, so you can compare them with actual results over time.

One of the top community narratives on Insmed: 45% undervalued

"The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3..."

Do you think there's more to the story for Insmed? Head over to our Community to see what others are saying!

The Bottom Line

For Insmed, the current market multiple points to an overvalued stock on sales, especially after a very large 3 year return and an extreme share price move. The key question is whether future revenue and earnings can grow into this richer P/S, or whether expectations have already stretched too far. From here, the crux of the bull versus bear debate is how much confidence you place in Insmed’s ability to turn its pipeline progress into durable, commercially meaningful cash flows without needing a lower valuation reset.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.